Clinical Trials Monitor/
RecruitingNCT07447908

Ted Rogers Understanding of Exacerbations in Heart Failure 2 (TRUE-HF2): Observational Study

Sponsor: University Health Network, Toronto

Trial Details

ConditionHeart Failure, Heart Failure - NYHA II - IV, Heart Failure Patients, Cardiopulmonary Exercise Test, Apple Watch
StatusRecruiting
Participants360
Est. Completion1 Sept 2029
Last Updated6 July 2026

Primary Outcome

Prediction of Cardiopulmonary Exercise Test Parameters; Prediction of worsening heart failure

Eligibility Criteria

Inclusion Criteria

Inclusion Criteria: * broad age range (\> 18 years of age) * NT-proBNP \> 400 or 1000 if in AF * Within 3 months post discharge from HF hospitalization/ HF ED visit/ HF rapid clinic visit with intensification of diuretic therapy * NYHA functional class I-IV, heart failure with reduced and preserved ejection fraction * Literacy in English * Patient provided informed consent Exclusion Criteria: * Unable to perform a CPET based on the standard protocol * End stage renal disease requiring dialysis * Living with LVAD * MRP deems patient unfit for the study * Post heart transplant

Trial Sites

Countries

Canada
View Registry Entry

Related Analysis

TRUE-HF2 Trial Opens: Can Apple Watch Biometrics Predict Heart Failure Exacerbations and CPET Parameters? — What Clinicians Need to Know

The TRUE-HF2 observational study, sponsored by the University Health Network in Toronto, is recruiting 360 heart failure patients to determine whether Apple Watch biometric data — combined with biomarkers and cardiac testing — can predict CPET parameters and anticipate HF exacerbations. The trial represents a landmark step toward integrating consumer wearables into evidence-based heart failure prognostication, with implications for remote monitoring and early intervention strategies globally.

Read full article →

This content is for educational purposes for healthcare professionals only and does not constitute clinical advice. Clinical decisions should be based on individual patient assessment, current guidelines, and appropriate specialist consultation. Editorial Standards · Privacy Policy · Terms of Service